Insider Selling: Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Sells $1,310,871.20 in Stock

November 4, 2026 by InsiderTrades.com

Key Points

Major shareholder Qiming sold 43,930 Alamar Biosciences shares for about $1.31 million at an average $29.84, reducing its ownership by 21.45% to 160,913 shares. The sale followed multiple other sales in October.
Alamar reported a third-quarter loss of $0.19 per share, narrower than analysts’ expected $0.22 loss, and revenue of $33.55 million; it also raised its 2026 revenue guidance.
The company announced research collaborations with GSK and on an 80,000-sample UK Biobank study, putting its NULISA platform into high-profile research projects; direct commercial impact was not specified.

Alamar Biosciences, Inc. (NASDAQ:ALMR - Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 43,930 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $29.84, for a total transaction of $1,310,871.20. Following the completion of the sale, the insider owned 160,913 shares of the company's stock, valued at $4,801,643.92. This trade represents a 21.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

On Friday, October 30th, Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.38, for a total transaction of $4,365,788.28.
On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The stock was sold at an average price of $32.77, for a total transaction of $3,304,428.49.
On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The shares were sold at an average price of $31.39, for a total transaction of $2,664,822.66.
On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total transaction of $4,044,632.48.
On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.59, for a total transaction of $4,525,301.06.
On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total transaction of $3,924,676.63.
On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total transaction of $6,329,182.65.
On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.89, for a total value of $3,960,491.56.
On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The shares were sold at an average price of $26.34, for a total value of $1,988,880.72.
On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total value of $3,674.72.

Alamar Biosciences Stock Up 4.4%

NASDAQ:ALMR opened at $30.22 on Wednesday. Alamar Biosciences, Inc. has a one year low of $18.84 and a one year high of $39.61. The company has a quick ratio of 10.23, a current ratio of 11.85 and a debt-to-equity ratio of 0.03. The firm has a 50 day moving average of $30.49.

Alamar Biosciences (NASDAQ:ALMR - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.03. The company had revenue of $33.55 million for the quarter. As a group, equities analysts forecast that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current fiscal year.

Key Alamar Biosciences News

Here are the key news stories impacting Alamar Biosciences this week:

Positive Sentiment: For Q3 2026, Alamar reported a loss of $0.19 per share, beating the $0.22-per-share loss consensus, and revenue of $33.55 million. The company also raised its 2026 revenue guidance, a potentially supportive signal for its growth outlook. Alamar reports Q3 results and raises 2026 revenue guidance
Positive Sentiment: Alamar announced a scientific collaboration with GSK using its NULISA platform in a large-scale study of protein signatures across several disease areas. The partnership could raise the platform’s profile, though no financial terms were disclosed. Alamar partners with GSK on proteomic study
Positive Sentiment: Alamar and Nightingale Health will lead an 80,000-sample UK Biobank study focused on neurodegenerative diseases, with support from major research organizations. The project may showcase Alamar’s technology in a significant research effort; direct commercial impact was not specified. Alamar and Nightingale to lead UK Biobank study
Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming disclosed sales totaling 187,636 shares across October 30 and November 2. Large-holder selling can weigh on sentiment, although the filings do not state the reason for the sales. SEC filing on shareholder transactions

Analysts Set New Price Targets

Several research analysts have recently commented on ALMR shares. TD Cowen reiterated a "buy" rating on shares of Alamar Biosciences in a report on Wednesday, July 15th. Weiss Ratings lowered shares of Alamar Biosciences from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, October 23rd. JPMorgan Chase & Co. upped their price objective on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an "overweight" rating in a report on Tuesday, August 11th. Finally, Stifel Nicolaus raised their price objective on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Alamar Biosciences currently has an average rating of "Hold" and a consensus price target of $31.80.

Check Out Our Latest Stock Analysis on ALMR

Institutional Trading of Alamar Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Braidwell LP acquired a new stake in shares of Alamar Biosciences during the 2nd quarter worth about $29,365,000. Wellington Management Group LLP acquired a new position in Alamar Biosciences in the second quarter valued at about $12,407,000. State Street Corp acquired a new position in Alamar Biosciences in the second quarter valued at about $3,930,000. Sumitomo Mitsui Trust Group Inc. boosted its stake in Alamar Biosciences by 18.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company's stock worth $2,280,000 after buying an additional 10,461 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in Alamar Biosciences during the second quarter worth about $283,000.

About Alamar Biosciences

(Get Free Report)

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.